Advertisement

Topics

Idhifa approval furthers Celgene's diversification goals

10:21 EDT 1 Aug 2017 | BioPharmaDive

Revlimid continues to make up 60% of Celgene's revenues, but a new product for acute myeloid leukemia could help spread the wealth.

Original Article: Idhifa approval furthers Celgene's diversification goals

NEXT ARTICLE

More From BioPortfolio on "Idhifa approval furthers Celgene's diversification goals"

Quick Search
Advertisement